Diagnostic Tests: Ringed Sideroblasts



Overview — What This Is

The cell shown is a ringed sideroblast, a pathological erythroblast with iron-loaded mitochondria encircling the nucleus. These iron deposits can only be seen clearly using a Prussian blue stain, which highlights the mitochondrial iron in a ring-like pattern. Ringed sideroblasts reflect a failure of the developing red blood cell to properly incorporate iron into heme during erythropoiesis.

What Causes This?


Ringed sideroblasts form when iron accumulates in mitochondria because of defective heme synthesis within erythroid precursors. This impairment leads to:

• Microcytic anemia
• Elevated serum iron level
• Ineffective erythropoiesis

Common causes of acquired sideroblastic anemia include:

• Alcohol use (most common)
• Drugs, such as:
  • Isoniazid (INH)
  • Chloramphenicol


• Toxins, including:
  • Lead
  • Zinc

These agents disrupt enzymes required for heme synthesis, especially ALA synthase, resulting in mitochondrial iron trapping.

Associated Hematologic Disorders

Ringed sideroblasts are the defining feature of sideroblastic anemia, but they are also associated with other disorders, including:

• Myelodysplastic Syndrome (MDS) — particularly the subtype known as refractory anemia with ring sideroblasts (RARS)
• Congenital sideroblastic anemias (less common, involve mutations in heme synthesis enzymes)

Thus, their presence should prompt evaluation for toxin exposure, alcohol use, medications, and underlying marrow disorders such as MDS.


If you’d like, I can create a comparison of sideroblastic anemia vs. iron deficiency anemia or provide a quick diagnostic algorithm for microcytic anemias.

Diagnostic Tests: Fragmented Red Blood Cells (Schistocytes)​

Overview — What This Is

The smear shows fragmented red blood cells, also referred to as schistocytes or helmet cells. These irregularly shaped RBC fragments form when erythrocytes are mechanically sheared within the circulation. Their presence is a hallmark of intravascular hemolysis and defines microangiopathic hemolytic anemia (MAHA).


Diseases Associated With Schistocytes

Fragmented RBCs occur in conditions where red cells are destroyed while passing through areas of fibrin deposition, turbulence, or mechanical injury. Major associated disorders include:

• Thrombotic Thrombocytopenic Purpura (TTP)
• Hemolytic Uremic Syndrome (HUS)
• Disseminated Intravascular Coagulation (DIC)
• Major blood group incompatibility (e.g., ABO mismatch)
• Paroxysmal Nocturnal Hemoglobinuria (PNH)
• Mechanical destruction from:
  • Artificial heart valves
  • Mechanical circulatory support devices (e.g., LVADs)


• Snake bites (due to hemotoxic venom effects)

These conditions share a common mechanism—red cell fragmentation within the vascular system.


Associated Laboratory Abnormalities

Because schistocytes signify intravascular hemolysis, several classic lab abnormalities accompany their presence:

• Elevated LDH — released from destroyed RBCs
• Elevated indirect (unconjugated) bilirubin — from heme breakdown
• Elevated reticulocyte count — bone marrow compensation
• Decreased haptoglobin — binds free hemoglobin, becomes depleted in intravascular hemolysis

These findings support the diagnosis of hemolysis and help distinguish MAHA from other causes of anemia.

Diagnostic Tests: Auer Rods


Overview — What This Is


The structure shown is an Auer rod, which is an eosinophilic, needle-shaped cytoplasmic inclusion found within myeloblasts or promyelocytes. These inclusions are composed of abnormal azurophilic granules and represent crystalline aggregates of myeloperoxidase. Their presence indicates a malignant proliferation of myeloid precursors.


Disease Associated With Auer Rods


Auer rods are pathognomonic for acute myelogenous leukemia (AML).
They may appear in several AML subtypes, but are especially prominent in:
• Acute Promyelocytic Leukemia (APL, M3) — often showing bundles of Auer rods (“faggot cells”), which is a high-yield test clue.


Their presence confirms the myeloid origin of the malignant blasts


When This Is the Correct Answer


You should answer Auer rods / AML when the question presents a patient with:
• Pancytopenia (fatigue, infections, bleeding)
• Peripheral smear showing blasts
• >20% blasts on bone marrow biopsy, meeting diagnostic criteria for acute leukemia
• Systemic symptoms such as fatigue, fever, infections, bruising, or bleeding


Additional diagnostic support includes:
• Myeloperoxidase (MPO) positivity on histochemical staining
• Expression of myeloid markers: CD13, CD33, CD117
• Presence of Auer rods confirms AML over ALL or other hematologic malignancies


In APL (t(15;17)), Auer rods are particularly dense and clinically important because the disease is associated with DIC, and treatment requires all-trans retinoic acid (ATRA).

Diagnostic Tests – PET Scanning

1. What Is a PET Scan?

A PET scan, or positron emission tomography, is an imaging technique that evaluates the metabolic activity of tissues rather than just their anatomical structure. Unlike CT or MRI, which show size, shape, and location, a PET scan uses a radioactive glucose analog—most commonly 18-fluorodeoxyglucose (FDG)—to assess how active a lesion is metabolically. Cancer cells typically have high glucose consumption, so they absorb more FDG and appear as areas of increased signal. PET scanning is noninvasive and is frequently used to determine whether a mass seen on other imaging studies is biologically active or whether it represents benign or inactive tissue.


2. What Makes a PET Scan Abnormal?

A PET scan is considered abnormal when there is increased uptake of FDG, indicating heightened metabolic activity. Malignant cells consume glucose rapidly because of their elevated growth and division rates, so they typically “light up” on PET imaging. Some infections, granulomatous diseases (e.g., TB, sarcoidosis), and inflammatory processes can also show increased uptake, which is why PET is not 100% specific for cancer. However, a low or absent uptake suggests that a lesion is metabolically inactive or benign, even if it appears concerning on CT or MRI.


3. When Is PET Scan the Correct Answer?

PET scanning is particularly useful when evaluating whether a lesion—such as a lung mass—is truly malignant or whether areas seen on CT represent metastatic disease. In oncology cases, PET is the answer when determining the functional status of a suspicious mass or when assessing for occult metastasis before deciding on surgical management. For example, if a patient is diagnosed with a localized lung tumor, a PET scan helps determine if there are metabolically active lesions elsewhere in the chest or body. If a contralateral mass or mediastinal lymph node lights up on PET, the disease is considered metastatic and surgery is no longer curative. Conversely, if additional lesions show low uptake, they are likely benign, and the patient may proceed safely to surgery to remove the primary tumor.

Diagnostic Tests – Papanicolaou (Pap) Smear

1. What Is a Pap Smear?

The Papanicolaou (Pap) smear is a cytologic screening test used to evaluate cells taken from the cervix in order to identify early precancerous changes or established cervical cancer. By examining exfoliated cervical cells under a microscope, clinicians can detect abnormalities caused primarily by high-risk HPV infections long before they progress to invasive disease. The Pap smear is one of the most effective screening tools in medicine and has significantly reduced cervical cancer mortality in populations where it is routinely used.


2. When Is Pap Smear the Correct Answer?

A Pap smear is indicated as a routine screening test for cervical cancer. Screening begins at age 21, regardless of sexual history, or earlier if guidelines specify onset within three years of first sexual activity; however, age 21 is the standard U.S. board-style answer. The test should be repeated every 2–3 years, depending on the screening strategy and incorporation of HPV co-testing. Screening may be discontinued at age 65 if the patient has had a history of adequate, consistently negative prior screenings and no recent abnormalities. Pap testing is used specifically for asymptomatic women as part of preventive care.


3. What Is the Next Best Test If Results Are Positive?

When a Pap smear shows abnormal cytology—whether atypical cells, low-grade changes, or high-grade lesions—the next step is to perform a colposcopy, during which the cervix is carefully examined under magnification. Suspicious areas are then biopsied to obtain tissue for definitive diagnosis. Colposcopy provides direct visualization of the transformation zone, allowing clinicians to identify the exact location and severity of cervical lesions and to determine appropriate management based on biopsy results.

Diagnostic Tests: Osmotic Fragility Test​

Overview

The osmotic fragility test is a diagnostic laboratory test used primarily in hematology to identify red blood cell (RBC) membrane defects. It is most famously associated with hereditary spherocytosis, a condition in which RBCs lose membrane surface area and become spherical in shape. Because of their altered structure, these cells are more susceptible to destruction when exposed to certain osmotic conditions. The test helps clinicians confirm the diagnosis in patients presenting with hemolytic anemia and characteristic findings on peripheral smear.


How the Test Works

The osmotic fragility test evaluates how easily RBCs lyse when placed in hypotonic (dilute) saline solutions. Normal red cells have a biconcave shape, giving them a high surface area-to-volume ratio and allowing them to tolerate changes in osmotic pressure. In contrast, spherocytes—such as those seen in hereditary spherocytosis—have reduced membrane surface area, making them less flexible and less able to expand when water enters the cell.


When placed in increasingly hypotonic solutions, spherocytes absorb water more rapidly and lyse at higher saline concentrations than normal cells. The degree of hemolysis is measured by the amount of hemoglobin released into the solution. A higher-than-normal level of hemolysis at moderate hypotonicity indicates increased osmotic fragility.


When Osmotic Fragility Is the Best Answer

You should choose osmotic fragility testing when evaluating a patient with features suggestive of hereditary spherocytosis, particularly when the case includes:

• Hemolytic anemia, often chronic or recurrent
• Splenomegaly
• Spherocytes on peripheral blood smear
• Family history of similar episodes
• Pigmented (bilirubin) gallstones, which develop from chronic hemolysis

These key clinical clues, combined with laboratory findings, strongly support the use of osmotic fragility testing as part of the diagnostic work-up.

Diagnostic Tests: Mixing Studies​

Overview

Mixing studies are specialized hematologic diagnostic tests used to evaluate the cause of a prolonged activated partial thromboplastin time (aPTT). When a patient presents with an elevated aPTT, clinicians must determine whether the abnormality results from a deficiency in one or more clotting factors or from the presence of an inhibitor that interferes with coagulation. The mixing study helps differentiate these two possibilities by combining the patient’s plasma with normal pooled plasma and reassessing the aPTT.

When Mixing Studies Are Most Useful

Mixing studies are the best initial diagnostic test when a patient has an isolated prolonged aPTT on coagulation screening. They are particularly valuable early in the diagnostic work-up when the clinical presentation suggests a bleeding disorder (such as hemophilia) or when the patient has unexplained clotting abnormalities that may be associated with an inhibitor such as lupus anticoagulant. Because the test quickly distinguishes between deficiency and inhibition, it guides the next steps in targeted laboratory evaluation.

Interpretation: When the aPTT Normalizes

If the prolonged aPTT corrects (normalizes) after mixing the patient’s plasma with normal plasma, the result strongly indicates a clotting factor deficiency. The normal plasma contains adequate amounts of missing factors, allowing the aPTT to return to normal. This pattern is characteristic of congenital or acquired deficiencies in factors such as VIII, IX, or XI. When correction occurs, clinicians should proceed with individual clotting factor assays to determine which specific factor is deficient and to assess its activity level.

Interpretation: When the aPTT Does Not Normalize

If the aPTT fails to correct after mixing, it suggests the presence of a circulating inhibitor. Inhibitors interfere with the clotting cascade even when normal plasma is added, preventing normalization of the aPTT. Common inhibitors include factor VIII inhibitors, seen in acquired hemophilia, and the lupus anticoagulant, associated with antiphospholipid antibody syndromes. In such cases, further diagnostic work-up is needed, often including inhibitor assays or testing for antiphospholipid antibodies.

Diagnostic Tests – Methylmalonic Acid (MMA) Level

Methylmalonic acid (MMA) is a metabolic compound that accumulates in the body when vitamin B12 is deficient. Because MMA rises early in B12 deficiency, it is more sensitive than simply measuring serum vitamin B12 levels. In contrast, homocysteine levels increase in both vitamin B12 deficiency and folic acid deficiency, making homocysteine less specific. Therefore, MMA is a key diagnostic marker when evaluating macrocytic anemia and suspected B12 deficiency, especially when initial tests are inconclusive.


MMA testing becomes particularly important when a patient presents with macrocytic anemia, hypersegmented neutrophils, or clinical features suggestive of vitamin B12 deficiency—such as peripheral neuropathy, glossitis, or a history of malabsorption—but has a normal or borderline serum B12 level. In these situations, B12 levels may not accurately reflect tissue-level deficiency. Thus, when the clinical scenario strongly points toward B12 deficiency but the measured B12 level appears normal, the correct next diagnostic step is to order an MMA level to confirm or rule out early or functional B12 deficiency.

Diagnostic Tests– Lymph Node Biopsy

A lymph node biopsy is performed to determine whether lymph node enlargement is due to infection, malignancy, or another underlying condition. The choice between a needle biopsy and an excisional biopsy depends entirely on the clinical suspicion and the characteristics of the lymph node. Proper selection is essential because certain conditions require specific types of tissue sampling to achieve an accurate diagnosis.


A needle biopsy is the correct choice when an infectious cause of lymphadenopathy is suspected. Infections such as tuberculosis, fungal infections, or bacterial infections (including Staphylococcus) can be diagnosed using needle aspiration because this method provides enough material for microbiologic studies. Clinically, infectious lymph nodes are often warm, tender, red, and sometimes fluctuant, reflecting inflammation. Because diagnosing infection does not require assessing the full architecture of the lymph node, a needle biopsy is usually sufficient.


An excisional biopsy is the best and most accurate test when lymphoma is suspected. Lymphoma requires examination of the complete lymph node architecture, which cannot be obtained through a needle biopsy. In fact, using a needle biopsy to diagnose lymphoma is a frequent wrong answer in exams because individual lymphocytes can appear normal on cytology, leading to missed diagnoses. Lymph nodes involved in lymphoma are typically nontender, firm, and not warm or red, distinguishing them from infectious nodes. When these features are present, an excisional biopsy is the appropriate diagnostic test.